Revenue
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Tvardi Therapeutics, Inc. (TVRD)
Price$1.91Cached quote
Net income
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $7.1M | $21.0M | $41.9M | $23.0M | $135.1M | $19.9M | $13.5M | $911,000 | $86,000 | $3.8M | $3.2M | $12.0M | $1.2M |
| Gross profit | — | — | — | — | $23.0M | — | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | 100.00% | — | — | — | — | — | — | — | — | — |
| Research & development | $18.0M | $23.6M | $108.5M | $91.9M | $82.7M | $107.9M | $113.8M | $75.5M | $48.5M | $49.3M | $21.2M | $15.1M | $8.7M | $4.6M |
| Operating expenses | $26.7M | $28.1M | $142.5M | $129.4M | $112.1M | $129.7M | $131.6M | $90.9M | $60.4M | $58.5M | $29.0M | $21.2M | $12.2M | $7.4M |
| Operating income | −$26.7M | −$28.1M | −$121.5M | −$87.5M | −$89.1M | $5.4M | −$111.7M | −$77.4M | −$59.5M | −$58.4M | −$25.2M | −$18.1M | −$237,000 | −$6.2M |
| Operating margin | — | −393.82% | −579.43% | −209.08% | −386.85% | 3.99% | −561.60% | −574.52% | −6,529.64% | −67,906.98% | −662.32% | −568.84% | −1.98% | −524.03% |
| EBITDA | −$26.7M | −$28.0M | −$121.2M | −$87.3M | −$88.8M | $5.6M | −$111.5M | −$77.0M | −$59.0M | −$56.9M | −$24.3M | −$17.3M | $552,000 | −$5.2M |
| EBITDA margin | — | −392.49% | −578.20% | −208.49% | −385.77% | 4.14% | −560.60% | −571.77% | −6,475.30% | −66,203.49% | −640.26% | −544.19% | 4.61% | −438.24% |
| Net income | −$18.2M | −$29.4M | −$118.5M | −$85.5M | −$88.4M | $8.4M | −$106.4M | −$74.0M | −$58.1M | −$57.3M | −$24.7M | −$17.7M | −$4.0M | −$6.3M |
| Net profit margin | — | −411.90% | −565.21% | −204.16% | −384.06% | 6.23% | −534.91% | −549.51% | −6,380.35% | −66,604.65% | −649.22% | −558.55% | −33.12% | −526.97% |
| Basic EPSper basic share | -$2.46 | -$11.42 | -$78.78 | -$57.36 | -$62.89 | $6.51 | -$90.00 | -$74.46 | -$67.23 | -$75.90 | -$36.14 | -$30.72 | -$26.75 | — |
| Diluted EPSper diluted share | -$3.26 | -$11.42 | -$78.78 | -$57.36 | -$62.89 | $6.51 | -$90.00 | -$74.46 | -$67.23 | -$75.90 | -$36.14 | -$30.72 | -$26.75 | — |
Owners
Reported shareholders
7.51%of listed shares
Slate Path Capital LP704.12K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Slate Path Capital LP | 7.51%704.12K shares |
Wirk Shaheen | ≈4.68%439.19K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.67%344.38K shares |
HALL WALLACE L JR | ≈2.63%246.76K shares |
AMERICAN FINANCIAL GROUP INC | 2.38%223.66K shares |
UBS Group AG | 1.18%111.13K shares |
SILVERCREST ASSET MANAGEMENT GROUP LLC | 1.08%101.03K shares |
BlackRock, Inc. | 1.02%95.48K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.97%91.41K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.96%90.35K shares |
MORGAN STANLEY | 0.83%77.85K shares |
Duncan Williams Asset Management, LLC | 0.67%63.24K shares |
VANGUARD FIDUCIARY TRUST CO | 0.48%44.71K shares |
Russell Investments Group, Ltd. | 0.46%43.23K shares |
STATE STREET CORP | 0.36%33.9K shares |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.35%33.17K shares |
AQR CAPITAL MANAGEMENT LLC | 0.29%27.1K shares |
NORTHERN TRUST CORP | 0.23%21.84K shares |
Savant Capital, LLC | 0.21%19.46K shares |
GSA CAPITAL PARTNERS LLP | 0.19%17.89K shares |
Percentages use 9.38M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 28, 2025Form 4 | Posner ChristopherPRESIDENT AND CEO | SellCommon Stock | 583 | $4.75 | $2.8K | 13.1K |
| Feb 28, 2025Form 4 | Terrillion ScottSEC'Y; CHIEF COMPLIANCE & G.C. | SellCommon Stock | 163 | $4.76 | $775.88 | 7.2K |
| Feb 4, 2025Form 4 | Posner ChristopherPRESIDENT AND CEO | SellCommon Stock | 372 | $4.72 | $1.8K | 13.7K |
| Nov 4, 2024Form 4 | Posner ChristopherPRESIDENT AND CEO | SellCommon Stock | 3.7K | $0.29 | $1.1K | 168.8K |
| Aug 1, 2024Form 4 | Posner ChristopherPRESIDENT AND CEO | SellCommon Stock | 4.1K | $0.35 | $1.5K | 172.4K |